BioCentury
ARTICLE | Emerging Company Profile

Danube: Taking the pressure off glaucoma

December 22, 2008 8:00 AM UTC

Danube Pharmaceuticals Inc. believes the mechanism of action of its lead compound for glaucoma could be both neuroprotective and disease-altering, giving it a leg up on beta blockers and prostaglandins, which are the standards of care.

Glaucoma is characterized by the buildup of aqueous humor in the eye, leading to increased intraocular pressure (IOP). Increased IOP destroys the axons on the retinal ganglion cells (RGCs), leading to cell death, vision loss and eventual blindness...